Latest news with #Element
Calgary Herald
26-05-2025
- Business
- Calgary Herald
Parker: Hospitality industry veteran Ostrem eager to take helm of new Element hotel in downtown Calgary
Article content Tim Ostrem has enjoyed three decades of experience in hospitality, an industry he is passionate about, and he is excited to take on the role of general manager of the Element by Westin Calgary Downtown that is expected to open next month. Article content Ostrem has gained a wealth of knowledge with managed, franchised and independent properties, holding senior roles in hotels where he delivered exceptional results. They include the Algonquin Resort, the former CP hotel at St. Andrews by-the-Sea in New Brunswick, after it became the first Autograph by Marriott hotel in Canada. Article content Article content The opportunity to manage a brand-new property has kindled his flame into a roar — he is in his element in the Element, super busy putting together his team. Leadership is in place and he currently has around 60 staff, with an expectation of 90 to 100 full- and part-time workers when the hotel is fully operational. Article content The Element is at 833 4 th Ave. S.W. in the former Canadian Centre office tower, a cornerstone conversion under the Downtown Calgary Development Incentive Program. Owned by Calgary-based PBA Group of Companies, it is a partnership between PBA and Concord Hospitality — the same relationship that brought us the Dorian, the 27-storey, dual-brand Marriott Autograph Collection and Courtyard Marriott hotel on 5th Avenue S.W. Article content Article content Occupied for many yeas as Mount Royal College, people will be shocked to see how the 12-storey, 170,000-square-foot office tower has been transformed into a modern, eco-friendly hotel featuring 226 spacious suites. Article content 'Being a refreshed and exciting new offering to Calgary's Downtown West neighbourhood is an incredibly rewarding experience — one that's only just beginning,' says Ostrem. 'We look forward to introducing the Element brand to Calgarians as the ideal place to stay, with many wellness features — as a place they can confidently recommend to friends and visitors.' Article content Atop the concrete construction is the rooftop level Bow & Bend restaurant — so named for its great view of the bend in the Bow River by Prince's Island. It is designed as an inviting social and dining experience, with space to seat 150 guests with indoor and outdoor seating and private dining room options.
Business Wire
22-05-2025
- Business
- Business Wire
Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions
SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced an expanded collaboration to enable Element's AVITI systems and Trinity flowcells with additional Twist library preparation and target enrichment workflows. 'This collaboration builds on our existing relationship with Element, which has yielded Twist's on-market Element-native kit and 1-hour fast hybridization Trinity solution. Twist will have exclusive access to develop additional library prep and target enrichment workflows compatible with Element's Trinity sequencing technology, giving Element customers access to the uniformity, consistency and quality provided by our NGS tools,' said Emily M. Leproust, CEO and co-founder of Twist Bioscience. 'This will further advance Twist and Element's shared goal to radically streamline hybrid capture processes both off and on the sequencer. With the expansion of our co-development and commercial efforts, we will be able to further serve critical markets such as agbio, population genomics and clinical research. Adapting our broadly compatible and innovative NGS workflows to work on Element's sequencing platform demonstrates the broad applicability and versatility of our NGS products and enables customers flexibility to choose the system that best meets their needs without sacrificing uniformity or quality delivered through the Twist portfolio.' "By uniting our revolutionary Trinity workflow for targeted sequencing with Twist's superior library preparation capabilities, we're creating an integrated solution that further catalyzes access to premium life science tools and accelerates scientific discovery across every field,' said Molly He, CEO and co-founder of Element Biosciences. 'Our partnership with Twist reflects both our companies' drive to remove barriers that have constrained innovation in this space for far too long." The collaboration between Twist and Element will enable researchers to access end-to-end workflows from library prep through sequencing on Element's AVITI platform, which offers high-quality sequencing and flexibility. Under the collaboration, Twist will be the exclusive partner of these new library prep and target enrichment workflows, expanding the existing Trinity offerings beyond exome sequencing and delivering industry-leading performance across key NGS applications. Twist and Element will engage in joint commercial and promotional activities to improve customer access to these innovative solutions. About Element Biosciences, Inc. Element Biosciences is a life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries. To learn more about Element, please visit and follow us on LinkedIn, X (Twitter), and Facebook. About Twist Bioscience Corporation At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit Follow us on LinkedIn | X | YouTube | Instagram | Bluesky Twist Bioscience Legal Notice Regarding Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Yahoo
22-05-2025
- Business
- Yahoo
Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions
Offer end-to-end workflow from library prep through sequencing Twist to be sole provider of new Trinity™ library prep and target enrichment kits for Element AVITI™ sequencer Joint commercial activities to expand customer access to new NGS tools SOUTH SAN FRANCISCO, Calif. & SAN DIEGO, May 22, 2025--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced an expanded collaboration to enable Element's AVITI systems and Trinity flowcells with additional Twist library preparation and target enrichment workflows. "This collaboration builds on our existing relationship with Element, which has yielded Twist's on-market Element-native kit and 1-hour fast hybridization Trinity solution. Twist will have exclusive access to develop additional library prep and target enrichment workflows compatible with Element's Trinity sequencing technology, giving Element customers access to the uniformity, consistency and quality provided by our NGS tools," said Emily M. Leproust, CEO and co-founder of Twist Bioscience. "This will further advance Twist and Element's shared goal to radically streamline hybrid capture processes both off and on the sequencer. With the expansion of our co-development and commercial efforts, we will be able to further serve critical markets such as agbio, population genomics and clinical research. Adapting our broadly compatible and innovative NGS workflows to work on Element's sequencing platform demonstrates the broad applicability and versatility of our NGS products and enables customers flexibility to choose the system that best meets their needs without sacrificing uniformity or quality delivered through the Twist portfolio." "By uniting our revolutionary Trinity workflow for targeted sequencing with Twist's superior library preparation capabilities, we're creating an integrated solution that further catalyzes access to premium life science tools and accelerates scientific discovery across every field," said Molly He, CEO and co-founder of Element Biosciences. "Our partnership with Twist reflects both our companies' drive to remove barriers that have constrained innovation in this space for far too long." The collaboration between Twist and Element will enable researchers to access end-to-end workflows from library prep through sequencing on Element's AVITI platform, which offers high-quality sequencing and flexibility. Under the collaboration, Twist will be the exclusive partner of these new library prep and target enrichment workflows, expanding the existing Trinity offerings beyond exome sequencing and delivering industry-leading performance across key NGS applications. Twist and Element will engage in joint commercial and promotional activities to improve customer access to these innovative solutions. About Element Biosciences, Inc. Element Biosciences is a life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries. To learn more about Element, please visit and follow us on LinkedIn, X (Twitter), and Facebook. About Twist Bioscience Corporation At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit Follow us on LinkedIn | X | YouTube | Instagram | Bluesky Twist Bioscience Legal Notice Regarding Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. View source version on Contacts FOR TWIST:For Investors: Angela BittingSVP, Corporate Affairs925-202-6211abitting@ For Media: Amanda HoulihanCommunications Manager774-265-5334ahoulihan@ FOR ELEMENT:Michael SullivanCorporate Communications Manager503-799-7520Media@ Sign in to access your portfolio
Irish Examiner
15-05-2025
- Entertainment
- Irish Examiner
Paul Mescal, Bono, dresscode... 10 things to watch out for at Cannes Film Festival
1. Paul Mescal The History of Sound competes for the top prize at Cannes, the Palme d'Or. It stars Paul Mescal and The Crown's Josh O'Connor in a drama set during World War I, which has already been drawing buzz ahead of its festival debut. The film centres on two men who want to record the lives and music of their compatriots. As they do so, they begin to fall in love. The drama from filmmaker Oliver Hermanus also has Mescal on board as an executive producer. 2. New dress rules Jury member Halle Berry had to mount a last-minute frock exchange when she learned of changes to the dress code at the festival this year. 'I had an amazing dress by Gupta that I cannot wear tonight because it's too big of a train,' Berry said. 'I'm not going to break the rules. The nudity part is also probably a good rule.' Changes include recommendations on 'voluminous outfits', in particular those with a large train, that hinder the proper flow of traffic of guests and complicate seating in the theatre. The nudity rule is 'not to regulate attire per se, but to prohibit full nudity on the red carpet, in accordance with the institutional framework of the event and French law,' according to the festival. 3. Pillion's Irish Connections Andrew Lowe and Ed Guiney from Dublin-based Element Pictures. Dublin-based production powerhouse Element Pictures — whose many previous successes include Room, Normal People and Poor Things —has two films selected for Cannes this year. Based on the book Box Hill by Adam Mars-Jones, Pillion is directed by Harry Lighton, stars Alexander Skarsgard and Harry Melling, and was shot on location in the UK. It tells the story of an unassuming man who is swept off his feet when an enigmatic biker takes him on as his submissive. 4. My Father's Shadow Element is also bringing the forthcoming My Father's Shadow— shot on location in Nigeria — to the acclaimed film festival. A semi-autobiographical tale set over the course of a single day in the Nigerian capital Lagos during the 1993 election crisis, it follows a father, estranged from his two young sons, as they travel through the city while political unrest threatens their journey home. 5. Bono Stories of Surrender, a reimagining of the U2 frontman's one-man autobiographical stage show, makes its debut at this year's festival. Directed by Australian filmmaker Andrew Dominik (Blonde, Chopper) the documentary will feature previously unseen footage from the tour as Bono pulls back the curtains on his life. It will also feature performances of many of the songs that have shaped the Dublin singer's life and musical legacy. 6. Learning to Breathe Under Water Filmed in Ireland, Learning to Breathe Under Water has been selected for the Great 8 showcase at the upcoming festival. Starring Rory Kinnear and Maria Bakalova (possibly familiar from Borat Subsequent Moviefilm) the film was made on location in Galway last year and introduces young Irish actor Ezra Carlisle in his first major screen role. The showcase will help ignite international interest in the comedy-drama - previous films selected include Kneecap and Aftersun. 7. Enda Walsh Enda Walsh co-wrote Die, My Love. Picture: Dan Linehan The Dublin writer recently collaborated with Cork stars Cillian Murphy and Eileen Walsh - who he first met through Corcadorca's Disco Pigs - on the adaptation of Claire Keegan's novel Small Things Like These. Now Enda Walsh is working with acclaimed filmmaker Lynne Ramsay on one of Cannes' buzziest titles. The Scottish filmmaker returns to the Croisette after her first film You Were Never Really Here won best screenplay at the 2017 festival. Walsh co-wrote Die, My Love with Ramsay and Alice Birch, an adaptation of a novel by Ariana Harwicz about a new mother who develops postpartum depression and psychosis. The impressive cast bringing the film to Cannes includes Jennifer Lawrence, Robert Pattinson, and Sissy Spacek. 8. The Palme d'Or A scene from The Phoenician Scheme, by Wes Anderson. Regarded as the most prestigious prize on the world's film festival circuit, the Palme d'Or can transform the success of and attention on a film, generating huge interest from both the public and the film industry. Just ask the makers of Anora, last year's Palme winner, which went on to win Best Picture at the Oscars. Among this year's many contenders are Wes Anderson, bringing his star-studded The Phoenician Scheme to the Croisette. US filmmaker Richard Linklater's Nouvelle Vague - which tells the story behind Jean Luc Godard's French classic A Bout de Souffle - will be a popular contender. Some of the female filmmakers in contention for the Palme d'Or include Mascha Schilinski ( Sound of Falling), Lynne Ramsay ( Die, My Love), and Carla Simón ( Romería). 9. Actors going behind the camera Some high-profile screen stars are turning directors with their latest projects. Kristen Stewart directs a cast that includes Imogen Posts and Thora Birch in an adaptation of Lidia Yuknavitch's bestseller The Chronology of Water. Scarlett Johansson makes her directorial debut with Eleanor the Great, which stars June Squibb as a woman who, after a devastating loss, tells a tale that takes on a dangerous life of its own. 10. The Palm Dog: Quentin Tarantino at a previous Palm Dog event. Cinema's most-talented pooches will be ready for their close-ups at this annual award for the top dog at Cannes. Always a quirky and popular event, the Palm Dog is presented to the most committed canine performance at each year's festival. Though intended as light relief as the festival draws to a close, the Palme Dog is not to be sniffed at - previous winners include Messi, the blue-eyed French border collie at the heart of Anatomy of a Fall, and Uggie, the jack russell terrier who stole moviegoers' hearts in The Artist. Cannes Film Festival runs until May 24
Hamilton Spectator
02-05-2025
- Automotive
- Hamilton Spectator
Element Announces Annual Meeting Voting Results
TORONTO, May 02, 2025 (GLOBE NEWSWIRE) — Element Fleet Management Corp. (TSX:EFN) ('Element' or the 'Company'), the largest publicly traded, pure-play automotive fleet manager in the world, confirmed today that all ten nominees listed in its management information circular dated March 19, 2025 were elected as directors at the Annual Meeting of Shareholders held on May 2, 2025 (the 'Meeting'), with each director receiving strong support as demonstrated by the results below. A total of 349,202,443 common shares (approximately 86.53% of the outstanding common shares) were represented in person or by proxy at the Meeting. 'We would like to thank our shareholders for their engagement, as demonstrated by turnout of over 86% of shares voted, and also for their continued support as evidenced by the strong voting outcomes,' said Kathleen Taylor, Chair of the Board. The detailed results of the vote for the election of directors at the Meeting are set out below: In addition, shareholders approved an advisory resolution (say on pay) on executive compensation with 97.51% of votes cast in favour of the resolution, and approved the re-appointment of Ernst & Young LLP as the Company's independent auditors. For complete results on all matters voted on at the Meeting, see Element's Report of Voting Results filed on the Company's SEDAR+ profile at . About Element Fleet Management Element Fleet Management (TSX: EFN) is the largest publicly traded pure-play automotive fleet manager in the world. As a Purpose-driven company, we provide a full range of sustainable and intelligent mobility solutions to optimize and enhance fleet performance for our clients across North America, Australia, and New Zealand. Our services address every aspect of our clients' fleet requirements, from vehicle acquisition, maintenance, route optimization, risk management, and remarketing, to advising on decarbonization efforts, integration of electric vehicles and managing the complexity of gradual fleet electrification. Clients benefit from Element's expertise as one of the largest fleet solutions providers in its markets, offering economies of scale and insight used to reduce operating costs and enhance efficiency and performance. At Element, we maximize our clients' fleet so they can focus on growing their business. For more information, please visit: Contact: This press release includes forward-looking statements regarding Element and its business. Such statements are based on management's current expectations and views of future events. In some cases the forward-looking statements can be identified by words or phrases such as 'may', 'will', 'expect', 'plan', 'anticipate', 'intend', 'potential', 'estimate', 'believe' or the negative of these terms, or other similar expressions intended to identify forward-looking statements. No forward-looking statement can be guaranteed. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause Element's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. Such risks and uncertainties include those regarding the fleet management and finance industries, economic factors, regulatory landscape and many other factors beyond the control of Element. A discussion of the material risks and assumptions associated with this outlook can be found in Element's annual MD&A, and Annual Information Form for the year ended December 31, 2024, each of which has been filed on SEDAR+ and can be accessed at . Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Element undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
